Company Overview of Invitae Corporation
Invitae Corporation, a genetic information company, provides genetic diagnostics for various hereditary disorders. The company provides gene sequencing and deletion/duplication analysis for disorders in various medical specialties that include cardiology, such as long and short QT syndrome, Brugada syndrome, and hypertrophic cardiomyopathy; hereditary cancers, including breast, ovarian, and endometrial cancers, as well as colon and pancreatic cancers; pediatric genetics; neurology; and hematology. It also offers tools, such as Family History Tool that enables users to digitally build, modify, share, and save patient pedigrees, as well as assess their risks and decide on the appropriate genet...
458 Brannan Street
San Francisco, CA 94107
Founded in 2012
Key Executives for Invitae Corporation
Chairman, Chief Executive Officer and Member of Strategy Team
Total Annual Compensation: $203.7K
Co-Founder, President, Chief Operating Officer, Member of Strategy Team and Director
Total Annual Compensation: $281.9K
Chief Commercial Officer and Member of Strategy Team
Total Annual Compensation: $286.6K
Compensation as of Fiscal Year 2014.
Invitae Corporation Key Developments
Invitae Corporation Presents at JPMorgan 34th Annual Healthcare Conference, Jan-13-2016 10:00 AM
Jan 6 16
Invitae Corporation Presents at JPMorgan 34th Annual Healthcare Conference, Jan-13-2016 10:00 AM. Venue: Westin St. Francis Hotel, 335 Powell Street, San Francisco, California, United States. Speakers: Randal W. Scott, Chairman, Chief Executive Officer and Member of Strategy Team.
Invitae Corporation Announces Expansion of Hereditary Cancer Testing Menu
Nov 18 15
Invitae Corporation announced that it has expanded its hereditary cancer genetic testing menu, now offering an even more comprehensive testing menu that covers all major hereditary cancers. The company has expanded its test menu to include blood, bone, brain, endocrine (hyperparathyroidism, thyroid cancer, and paraganglioma-pheochromocytoma), genitourinary (renal/urinary tract and prostate cancer), sarcoma, and skin cancers (melanoma and basal cell nevus syndrome). This expanded test menu is offered at the same price and with the same flexibility as all of company's genetic tests. In addition, the company is introducing three new, focused panels based entirely on oncology management guidelines in breast, gynecologic, and colon cancer. The company also offers epidermal growth factor receptor (EGFR) testing for patients with strong personal and family history of lung cancer, particularly when there is no history of environmental exposures such as tobacco smoking or radon.
Invitae Corporation Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2015; Revises Production Guidance for the Year 2015
Nov 5 15
Invitae Corporation reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2015. For the quarter, the company reported revenues of USD 2,187,000 compared to USD 310,000 a year ago. Loss from operations was USD 22,456,000 compared to USD 12,534,000 a year ago. Net loss was USD 22,527,000 compared to USD 12,615,000 a year ago. Basic and diluted net loss per share was USD 0.71 compared to USD 14.24 a year ago.
For the nine months, the company reported revenues of USD 5,217,000 compared to USD 729,000 a year ago. Loss from operations was USD 65,186,000 compared to USD 32,069,000 a year ago. Net loss was USD 65,422,000 compared to USD 32,187,000 a year ago. Basic and diluted net loss per share was USD 2.43 compared to USD 39.27 a year ago.
The company has raised its 2015 guidance for billable tests delivered to 17,000-19,000 for the year, up from its previous guidance of 16,000-18,000 billable tests delivered.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|